Interpreta's Leadership Team
Ahmed Ghouri, M.D.
Founder and Chief Executive Officer
Dr. Ahmed Ghouri co-founded Interpreta in 2014 and currently serves as Interpreta’s Chief Executive Officer and as a director. Prior to founding Interpreta, Dr. Ghouri was a founder and Chief Executive Officer at Anvita, a clinical analytics company acquired by Humana in 2011. Dr. Ghouri is the principal author of 70+ peer reviewed scientific publications and lead author on eight granted US Patents in analytics, medical devices and software. He was a co-lead investigator leading to the FDA approval of new drugs Flumazenil (the first Benzodiazepine reversal drug) and Desflurane (the first ultra-rapid general anesthetic). Dr. Ghouri holds an M.D. from Washington University, School of Medicine where he also completed a biomedical engineering fellowship. He is a board-certified anesthesiologist.
Founder and President
Raghu Sugavanam co-founded Interpreta in 2014 and currently serves as Interpreta’s President. Prior to founding Interpreta, Mr. Sugavanam was a founder, Chief Technology Officer and Principal Architect at Anvita, a clinical analytics company acquired by Humana in 2011. Prior to Anvita, he was a founder and President at Mercantile Software Systems, a high-performance database marketing system company acquired by Harte-Hanks in 1997. He holds an M.S. in Computer Science from Rutgers University, an M.S. in Chemical Engineering from Washington University in St. Louis, and a B.S. in Chemical Engineering from the Indian Institute of Technology in Madras.
Senior Management Team
Steven Fouskarinis, MBA
Vice President, Client Services
Steven Fouskarinis is Interpreta's Vice President of Client Services. Prior to joining Interpreta, Mr. Fouskarinis was with Optum360 for 5 years as its National Director of Client Services for Revenue Cycle Technology focused on providers using analytics to pinpoint errors, redundancies, and missed opportunities. Prior to that, he was the Director of Account Management and Program Management at Awarepoint Corporation, leading the largest active RFID deployment in the world for Kaiser Permanente. Before Awarepoint, Mr. Fouskarinis worked for several years in healthcare consulting, advising, and assisting a range of companies from specialized EMR vendors to world-renowned healthcare clinics and venture capital funds. Mr. Fouskarinis has an MBA from the IESE Business School, and dual B.S. degrees in Electrical Engineering and Computer Science from the University of Sydney.
Jiong Huang, Ph.D.
Vice President, Quality Management
Dr. Huang joined Interpreta in 2018 as Vice President of Quality Management. Prior to joining Interpreta, Dr. Huang was with Amerigroup/Anthem for 12 years and led the enterprise quality data management team to manage national and state HEDIS®/HEDIS®-like reporting for all LOBs and end user enablement for care gap closure. Dr. Huang has nearly 20 years of HEDIS®operation management experience in the national and local setting, and an extensive background in quality measure development, data management, quality incentive programs, quality evaluation programs, and related audits. Dr. Huang received his Ph.D. in Chemistry from New York University, an M.S. in Business Information Management from Zicklin School of Business in Baruch College, and a B.S. in Materials Science and Engineering from University of Science and Technology of China.
Steve Kempf, Jr., MBA
Vice President, Client Solutions
Steve Kempf Jr. joined in 2016 and currently serves as Interpreta's Vice President of Client Solutions. Prior to joining Interpreta, Mr. Kempf was with Humana for 10 years. He was Vice President of Strategic Accounts for Anvita Health, a clinical analytics company acquired by Humana in 2011. Prior to that, he was a Director in Clinical Strategy and Technology at Humana, leading member and provider interventions for the success of Medicare and Commercial LOBs. Before Humana, Mr. Kempf worked for seven years at Norton Healthcare, Kentucky's largest healthcare delivery system, in the Cancer Center and revenue cycle operations. He was also recognized with the “Forty under 40” award from Business First in 2007. Mr. Kempf obtained a Master’s degree in Business Administration and a Bachelor’s degree in Biology from the University of Louisville.
Norman Winarsky, Ph.D.
Vice President, Artificial Intelligence and Natural Language Analytics
Dr. Norman Winarsky leads Interpreta’s artificial intelligence strategy, overseeing development of voice, image, and natural language understanding. He is a co-founder and founding board member of Siri. As President of SRI Ventures, he developed some of SRI's highest value opportunities, including Siri, Nuance, Intuitive Surgical, and many others whose total market value exceeds $50 billion. Dr. Winarsky is a Stanford Graduate School of Business lecturer and co-author of “If You Really Want to Change the World: A Guide to Creating, Building, and Sustaining Breakthrough Ventures.” He is a Strategic Advisor to the American Medical Association, and was a National Science Foundation Fellow. In 2000, Dr. Winarsky and his team received an Emmy Award for innovation in HDTV, as well as RCA's prominent Sarnoff Award. He received a Ph.D. in mathematics from the University of Chicago.
Benjamin Yu, M.D., Ph.D.
Vice President, Medical Informatics and Genomics
Dr. Benjamin Yu joined in 2014 and currently serves as Vice President, Clinical Informatics and Genomics. Prior to joining Interpreta, Dr. Yu was a faculty member of the University of California San Diego and Institute for Genomic Medicine. Dr. Yu brings his experience as a leader in human variation and genomics. His publications in Nature, Cell Stem Cell, Developmental Cell and others have received over 2000 citations, and under his leadership his laboratory received more than 10 years of funding from NIH, California Institute for Regenerative Medicine, and the Bill and Melinda Gates Foundation. Dr. Yu received his M.D., Ph.D. and residency training at Washington University. Dr. Yu is board-certified in dermatology and has been licensed to practice medicine in California since 2002. He continues to participate in training new students and residents in dermatology and genetics, and advises on San Diego's Biocom Big Data Committee.